BREAKING: Novo Nordisk, maker of Ozempic and Wegovy, raised its full-year forecast after strong second-quarter profit driven by sales of a new Wegovy tablet, which launched in the US in January and was recently approved in Europe. 🔴 More on https://t.co/5H0QqpggO4 https://t.co/Psov3vp4SN